JNJ

Johnson & Johnson

256.44 USD

Last updated Oct 9, 05:09 UTC

Yesterday HIGH

$260.68

Yesterday LOW

$255.73

52w HIGH

$281.07

52w LOW

$182.94

EPS

2.90

PE

88.43

Next Earnings

Oct 13, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Johnson & Johnson stock is down -3.98% since 30 days ago. The next earnings date is Oct 13, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64% of the previous 49 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 6 CALLs, 4 PUTs. 75% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

08 Oct 14:34	18 Dec, 2026	250.00	CALL	123	2988
08 Oct 14:55	09 Oct, 2026	252.50	PUT	341	334
08 Oct 14:57	18 Dec, 2026	250.00	CALL	31	2988
08 Oct 15:01	16 Oct, 2026	252.50	PUT	502	190
08 Oct 15:04	17 Dec, 2027	220.00	CALL	11	145
08 Oct 16:03	17 Sep, 2027	280.00	CALL	195	224
08 Oct 16:33	19 Jan, 2029	250.00	PUT	29	0
08 Oct 16:36	09 Oct, 2026	252.50	PUT	500	334
08 Oct 18:34	23 Oct, 2026	262.50	CALL	77	114
08 Oct 19:02	18 Dec, 2026	250.00	CALL	20	2988

Advanced Data Unlock

Benzinga Insights

Fri Sep 18, 2026

9 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Chris Katje

Tue Sep 15, 2026

Senator Bets on Small Cap Stocks Ahead of Likely Rate Hike: Why That Could be Risky

A U.S. senator has added small cap stock ETFs to his portfolio ahead of a potential Federal Reserve rate hike. Here's why the timing matters.
Vandana Singh

Tue Sep 15, 2026

Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival

Johnson & Johnson released positive Phase 2b and Phase 3 trial results for its Rybrevant lung cancer treatment combinations.
Vandana Singh

Tue Sep 15, 2026

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.
Benzinga Newsdesk

Tue Sep 15, 2026

Reported Earlier, J&J's Subcutaneous RYBREVANT FASPRO Plus LAZCLUZE Shows Lower Rash, Administration-Related Reaction, Venous Thromboembolism Rates Than Intravenous MARIPOSA Regimen

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxisFewer than 1% of patients discontinued treatment due to treatment-related events at one
Benzinga Newsdesk

Mon Sep 14, 2026

Contineum’s Phase 2 MOONLIGHT-1 Trial Of JNJ-5120/PIPE-307 Did Not Meet Its Primary Efficacy Endpoint; Analyses Of The Data, Including Prespecified Exploratory Endpoints, Are Ongoing

Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpointAnalyses of the data, including prespecified exploratory endpoints, are ongoingContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a
Benzinga Newsdesk

Mon Sep 14, 2026

Johnson & Johnson’s RYBREVANT Combination Extends Survival To 34.3 Months In EGFR Exon 20+ Lung Cancer

https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer
Benzinga Newsdesk

Mon Sep 14, 2026

Reported Earlier, Johnson & Johnson Says Rybrevant Plus Chemotherapy Cuts Risk Of Death By 43% Versus Chemotherapy Alone When Adjusted For Crossover In Final PAPILLON Overall Survival Analysis

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and METResults mark significant progress for a patient population with poor outcomes and a historical
Chris Katje

Fri Sep 11, 2026

Richest NFL Team Owners List: Who’s Most Connected to Stock Market?

The list of NFL team owners includes billionaires and families. Some of them are well connected to publicly traded companies.
Benzinga Insights

Fri Sep 11, 2026

10 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will

RBC Capital

Tue Oct 6, 15:14

buy

confirm
Citigroup

Mon Oct 5, 21:43

buy

confirm
JP Morgan

Tue Sep 29, 15:29

hold

confirm
HSBC

Thu Sep 10, 15:42

buy

confirm

Advanced Data Unlock

Daniel E Pinto, Director

Tue Sep 8, 2026

JNJ Recent Insider Trades and Stock Chart

113.1 shares awarded
Eugene A Woods, Director

Tue Sep 8, 2026

JNJ Recent Insider Trades and Stock Chart

135.72 shares awarded
Marillyn A Hewson, Director

Tue Sep 8, 2026

JNJ Recent Insider Trades and Stock Chart

180.96 shares awarded